Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (374)	6/9/2005 2:17:36 AM
From: tuck	Respond to of 671

ALNY continues to look as though they've got the best IP so far. I still think that area of the RNAi space is murky, and will be so for a number of years, bwdik . . . >>CAMBRIDGE, Mass. and AUSTIN, Texas, June 8 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today that it has granted Ambion, Inc. a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family covers short interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells. "This agreement with Ambion reflects the value and strength of the intellectual property portfolio owned by Alnylam," said Vincent Miles, Ph.D., Senior Vice President, Business Development of Alnylam Pharmaceuticals. "With this agreement, Ambion, a recognized leader in the growing field of RNAi research products and services, becomes the fifth research products supplier, and the tenth company overall, to take a license for therapeutic or research product applications under fundamental intellectual property owned by Alnylam in the RNAi field." "Ambion is committed to leadership in RNA-based life sciences research, particularly in RNAi," said Matt Winkler, CEO and CSO of Ambion. "Licensing the Kreutzer-Limmer patent family from Alnylam further enables Ambion to confidently provide the scientific research community with the tools it needs in this field." On May 11, 2005, Alnylam announced that the European Patent Office granted a new patent that significantly extended the claims of the original Kreutzer-Limmer patent. These broad new claims cover compositions, uses, and methods for siRNAs, the molecules that mediate RNAi.<< snip Cheers, Tuck